Intech Investment Management LLC Trims Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Intech Investment Management LLC reduced its stake in Regeneron Pharmaceuticals by 44.3%, holding 7,985 shares worth approximately $5.06 million after selling 6,356 shares.
• Regeneron Pharmaceuticals reported a quarterly earnings per share (EPS) of $12.89, exceeding the expected $8.43 by $4.46, with revenues of $3.68 billion.
• The company announced a quarterly dividend of $0.88, resulting in an annualized dividend yield of 0.6%, and it has a low dividend payout ratio of 8.87%.

Intech Investment Management LLC lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 44.3% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 7,985 shares of the biopharmaceutical company's stock after selling 6,356 shares during the quarter. Intech Investment Management LLC's holdings in Regeneron Pharmaceuticals were worth $5,064,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Integrity Alliance LLC. bought a new stake in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $579,000. Anchor Investment Management LLC lifted its position in Regeneron Pharmaceuticals by 19.0% in the first quarter. Anchor Investment Management LLC now owns 1,196 shares of the biopharmaceutical company's stock worth $759,000 after buying an additional 191 shares during the last quarter. Glenview Trust co grew its stake in Regeneron Pharmaceuticals by 14.5% in the 1st quarter. Glenview Trust co now owns 3,515 shares of the biopharmaceutical company's stock worth $2,229,000 after acquiring an additional 444 shares in the last quarter. Ilmarinen Mutual Pension Insurance Co raised its position in Regeneron Pharmaceuticals by 30.7% during the 1st quarter. Ilmarinen Mutual Pension Insurance Co now owns 14,900 shares of the biopharmaceutical company's stock valued at $9,450,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Plato Investment Management Ltd lifted its holdings in shares of Regeneron Pharmaceuticals by 41.9% in the 1st quarter. Plato Investment Management Ltd now owns 3,777 shares of the biopharmaceutical company's stock worth $2,421,000 after buying an additional 1,116 shares during the period. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN traded up $2.47 during midday trading on Tuesday, hitting $575.06. The company had a trading volume of 707,913 shares, compared to its average volume of 1,094,070. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,165.85. The stock has a market cap of $60.95 billion, a price-to-earnings ratio of 14.49, a price-to-earnings-growth ratio of 1.87 and a beta of 0.35. The business's 50-day simple moving average is $565.30 and its 200-day simple moving average is $577.02. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The business had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same period in the prior year, the business posted $11.56 EPS. The company's revenue was up 3.6% compared to the same quarter last year. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Wall Street Analyst Weigh In

REGN has been the subject of several recent research reports. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a report on Friday, August 1st. UBS Group restated a "neutral" rating on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a "buy" rating in a report on Friday, August 1st. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating for the company in a research note on Monday, August 11th. Finally, Sanford C. Bernstein increased their price objective on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 27th. Three investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.